| Overview |
| bsm-51582M |
| MAGED1 Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| KLH conjugated synthetic peptide derived from human MAGED1 |
| 50-200/778 |
| Monoclonal |
| C5D3 |
| 0.5ug/ul |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 9500 |
| Q9Y5V3 |
| Cytoplasm, Nucleus, Cell membrane |
| DLXIN 1; MAGD1_HUMAN; MAGE D1 antigen; MAGE tumor antigen CCF; MAGE-D1 antigen; Melanoma antigen family D 1; Melanoma associated antigen D1; Melanoma-associated antigen D1; Neurotrophin receptor interacting MAGE homolog; Neurotrophin receptor-interacting MAGE homolog; NRAGE; PP2250. |
| Involved in the apoptotic response after nerve growthfactor (NGF) binding in neuronal cells. Binds NGFR/p75NTR andantagonizes its association with NTRK1/TrkA, inhibits cell cycleprogression, and facilitates NGFR-mediated apoptosis. May act as aregulator of the function of DLX family members. May regulateTP53/p53 transcriptional activity and inhibit cell proliferation.Enhances TP53 phosphorylation and accumulation. May enhanceubiquitin ligase activity of RING-type zinc finger-containing E3ubiquitin-protein ligases. Proposed to act through recruitmentand/or stabilization of the Ubl-conjugating enzyme (E2) at theE3:substrate complex. |
| Application Dilution |
| WB |
=1:500-1000， |
Powered by Bioz